Parkinson's disease therapy developer Aspen Neuroscience (ASPE.US) has an IPO price of $15-17 per share and plans to raise US$150 million

The Zhitong Finance App learned that Aspen Neuroscience (Aspen Neuroscience), a clinical-stage biotech company developing stem cell therapy for Parkinson's disease, announced the IPO terms on Monday. The San Diego, California-based company plans to raise $150 million by issuing 9.4 million shares at a price of $15 to $17 each. Based on the median value of the proposed distribution range, Aspen Neuroscience's fully diluted market value is approximately $494 million.

Aspen Neuroscience is dedicated to developing autoinduced pluripotent stem cell (iPSC) -derived therapies for neurodegenerative diseases. Its main candidate product, sasineprocel, is a single-dose cell therapy made from cells taken from patients' own skin biopsies to replace dopaminergic neurons lost in Parkinson's disease. The company is conducting an open-label phase 1/2a clinical trial to evaluate the efficacy of its drug sasineprocel. As of August 18, 2026, 15 patients have received the medication; according to FDA feedback, the company expects to administer the drug to patients in a phase III trial in the second half of 2027. SasineProcel has been certified by the FDA for Advanced Regenerative Medicine (RMAT) and Fast Track (Fast Track).

Aspen Neuroscience was founded in 2018 and plans to list on the NASDAQ under the code “ASPE.” Leerink Partners, Piper Sandler, Stifel, UBS Investment Bank, and Oppenheimer & Co. were co-underwriters for the deal. Pricing is expected for the week of October 26, 2026.